U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 4

1.
FIG 1.

FIG 1. From: SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer.

Probability of discontinuing adjuvant erlotinib in the study population.

Nathan A. Pennell, et al. J Clin Oncol. 2019 Jan 10;37(2):97-104.
2.
FIG 3.

FIG 3. From: SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer.

Probability of continuing to take a second course of erlotinib in patients with recurrence.

Nathan A. Pennell, et al. J Clin Oncol. 2019 Jan 10;37(2):97-104.
3.
FIG 2.

FIG 2. From: SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer.

(A) Disease-free survival in the overall study population. (B) Disease-free survival by pathologic stage.

Nathan A. Pennell, et al. J Clin Oncol. 2019 Jan 10;37(2):97-104.
4.
FIG 4.

FIG 4. From: SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer.

Swimmer plot of all patients who experienced disease recurrence (n = 40). The time receiving adjuvant erlotinib (light blue), time after adjuvant treatment before disease recurrence (red), and time receiving retreatment with erlotinib (teal) are illustrated. Arrows indicate that the patient continues to take erlotinib at data cutoff. TKI, tyrosine kinase inhibitor.

Nathan A. Pennell, et al. J Clin Oncol. 2019 Jan 10;37(2):97-104.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center